Please enable JavaScript to continue using this application.

Compare $AKBA vs $EVMN | Chartloom

Compare

$AKBA vs $EVMN

Akebia Therapeutics Inc · Evommune Inc

AKBA

Akebia Therapeutics Inc

EVMN

Evommune Inc

Compare $AKBA vs $EVMN

Comparing Akebia Therapeutics Inc and Evommune Inc

AKBAAkebia Therapeutics Inc

EVMNEvommune Inc

AKBAAkebia Therapeutics Inc

Market cap

$215M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1.35x

Rev growth (TTM)

7.5%

YTD performance

-48.3%

52W performance

-71.9%

FCF yield

13.7%

EVMNEvommune Inc

Market cap

$225M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-63.9%

52W performance

-69.1%

FCF yield

-55.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AKBA

EVMN

Detailed metrics comparison

AKBA

Akebia Therapeutics Inc

EVMN

Evommune Inc

Market Cap

AKBA$215M

EVMN$225M

Enterprise Value

AKBA$252M

EVMN$166M

Price

AKBA$0.80

EVMN$6.25

P/E Ratio

AKBAN/A

EVMNN/A

P/S Ratio

AKBA0.98x

EVMN14.07x

EV/Sales

AKBA1.15x

EVMN10.38x

EV/EBITDA

AKBA49.22x

EVMN0.00x

P/B Ratio

AKBA9.58x

EVMN0.90x

P/FCF Ratio

AKBA7.30x

EVMNN/A

EV/FCF

AKBA8.54x

EVMN-1.33x

PEG Ratio

AKBAN/A

EVMNN/A

Forward P/E (NTM)

AKBAN/A

EVMNN/A

Forward P/S (NTM)

AKBA1.35x

EVMNN/A

Revenue (TTM)

AKBA$219M

EVMN$16M

Revenue Growth (YoY)

AKBA7.5%

EVMNN/A

Forward Rev Growth

AKBA-33.0%

EVMN881.5%

Gross Margin (TTM)

AKBA81.5%

EVMN0.0%

Operating Margin (TTM)

AKBA0.0%

EVMN0.0%

EBITDA Margin (TTM)

AKBA-1.9%

EVMN-1097.9%

Net Margin (TTM)

AKBA-13.5%

EVMN-943.2%

FCF Margin (TTM)

AKBA13.4%

EVMN-779.8%

Net Income (TTM)

AKBA$-30M

EVMN$-151M

FCF (TTM)

AKBA$29M

EVMN$-125M

EPS (TTM)

AKBA-$0.11

EVMN-$4.18

ROE (TTM)

AKBA-9374.0%

EVMN-4676.0%

ROA (TTM)

AKBA-817.0%

EVMN-4337.0%

ROIC (TTM)

AKBA-1321.0%

EVMN-4661.0%

Cash

AKBA$156M

EVMN$60M

Debt

AKBA$192M

EVMN$952K

Net Cash/Debt

AKBA$-37M

EVMN$59M

Current Ratio (TTM)

AKBA1.43x

EVMN11.68x

Quick Ratio (TTM)

AKBA1.31x

EVMN11.48x

Debt/Equity (TTM)

AKBA7.69x

EVMN0.00x

Debt/Assets (TTM)

AKBA0.0%

EVMN0.0%

Interest Coverage (TTM)

AKBAN/A

EVMNN/A

Net Debt/EBITDA (TTM)

AKBA0.00x

EVMN0.00x

Beta

AKBA0.20

EVMN0.62

52W Performance

AKBA-71.9%

EVMN-69.1%

YTD Performance

AKBA-48.3%

EVMN-63.9%

% from 52W High

AKBA-75.0%

EVMN-81.2%

% from 52W Low

AKBA0.0%

EVMN3.8%

Asset Turnover (TTM)

AKBA0.60x

EVMN0.00x

FCF Yield (TTM)

AKBA13.7%

EVMN-55.4%

Earnings Yield (TTM)

AKBA-13.8%

EVMN-67.0%

Dividend Yield (TTM)

AKBAN/A

EVMNN/A

Rule of 40

AKBA21.0

EVMN-779.8

EV/GP/RG

AKBAN/A

EVMNN/A

Ticker research

View AKBA research View EVMN research

Metric	AKBA Akebia Therapeutics Inc	EVMN Evommune Inc
Market & Valuation
Market Cap	$215M	$225M
Enterprise Value	$252M	$166M
Price	$0.80	$6.25
P/E Ratio	N/A	N/A
P/S Ratio	0.98x	14.07x
EV/Sales	1.15x	10.38x
EV/EBITDA	49.22x	0.00x
P/B Ratio	9.58x	0.90x
P/FCF Ratio	7.30x	N/A
EV/FCF	8.54x	-1.33x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.35x	N/A
Revenue & Growth
Revenue (TTM)	$219M	$16M
Revenue Growth (YoY)	7.5%	N/A
Forward Rev Growth	-33.0%	881.5%
Profitability
Gross Margin (TTM)	81.5%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1.9%	-1097.9%
Net Margin (TTM)	-13.5%	-943.2%
FCF Margin (TTM)	13.4%	-779.8%
Net Income (TTM)	$-30M	$-151M
FCF (TTM)	$29M	$-125M
EPS (TTM)	-$0.11	-$4.18
ROE (TTM)	-9374.0%	-4676.0%
ROA (TTM)	-817.0%	-4337.0%
ROIC (TTM)	-1321.0%	-4661.0%
Financial Health
Cash	$156M	$60M
Debt	$192M	$952K
Net Cash/Debt	$-37M	$59M
Current Ratio (TTM)	1.43x	11.68x
Quick Ratio (TTM)	1.31x	11.48x
Debt/Equity (TTM)	7.69x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.20	0.62
52W Performance	-71.9%	-69.1%
YTD Performance	-48.3%	-63.9%
% from 52W High	-75.0%	-81.2%
% from 52W Low	0.0%	3.8%
Efficiency & Yields
Asset Turnover (TTM)	0.60x	0.00x
FCF Yield (TTM)	13.7%	-55.4%
Earnings Yield (TTM)	-13.8%	-67.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	21.0	-779.8
EV/GP/RG	N/A	N/A
Ticker research	View AKBA research	View EVMN research

Valuation

P/S Ratio

AKBA

0.98x

EVMN

14.07x

EV/FCF

EVMN

-1.33x

AKBA

8.54x

Growth & revenue

Revenue Growth TTM

AKBA

7.5%

Forward Revenue Growth

EVMN

881.5%

AKBA

-33.0%

Profitability & performance

Gross Margin

AKBA

81.5%

EVMN

0.0%

ROE

EVMN

-4676.0%

AKBA

-9374.0%

FCF Yield %

AKBA

13.7%

EVMN

-55.4%

52-Week Performance

EVMN

-69.1%

AKBA

-71.9%

Detailed metrics comparison

AKBA

Akebia Therapeutics Inc

EVMN

Evommune Inc

Market Cap

AKBA$215M

EVMN$225M

Enterprise Value

AKBA$252M

EVMN$166M

Price

AKBA$0.80

EVMN$6.25

P/E Ratio

AKBAN/A

EVMNN/A

P/S Ratio

AKBA0.98x

EVMN14.07x

EV/Sales

AKBA1.15x

EVMN10.38x

EV/EBITDA

AKBA49.22x

EVMN0.00x

P/B Ratio

AKBA9.58x

EVMN0.90x

P/FCF Ratio

AKBA7.30x

EVMNN/A

EV/FCF

AKBA8.54x

EVMN-1.33x

PEG Ratio

AKBAN/A

EVMNN/A

Forward P/E (NTM)

AKBAN/A

EVMNN/A

Forward P/S (NTM)

AKBA1.35x

EVMNN/A

Revenue (TTM)

AKBA$219M

EVMN$16M

Revenue Growth (YoY)

AKBA7.5%

EVMNN/A

Forward Rev Growth

AKBA-33.0%

EVMN881.5%

Gross Margin (TTM)

AKBA81.5%

EVMN0.0%

Operating Margin (TTM)

AKBA0.0%

EVMN0.0%

EBITDA Margin (TTM)

AKBA-1.9%

EVMN-1097.9%

Net Margin (TTM)

AKBA-13.5%

EVMN-943.2%

FCF Margin (TTM)

AKBA13.4%

EVMN-779.8%

Net Income (TTM)

AKBA$-30M

EVMN$-151M

FCF (TTM)

AKBA$29M

EVMN$-125M

EPS (TTM)

AKBA-$0.11

EVMN-$4.18

ROE (TTM)

AKBA-9374.0%

EVMN-4676.0%

ROA (TTM)

AKBA-817.0%

EVMN-4337.0%

ROIC (TTM)

AKBA-1321.0%

EVMN-4661.0%

Cash

AKBA$156M

EVMN$60M

Debt

AKBA$192M

EVMN$952K

Net Cash/Debt

AKBA$-37M

EVMN$59M

Current Ratio (TTM)

AKBA1.43x

EVMN11.68x

Quick Ratio (TTM)

AKBA1.31x

EVMN11.48x

Debt/Equity (TTM)

AKBA7.69x

EVMN0.00x

Debt/Assets (TTM)

AKBA0.0%

EVMN0.0%

Interest Coverage (TTM)

AKBAN/A

EVMNN/A

Net Debt/EBITDA (TTM)

AKBA0.00x

EVMN0.00x

Beta

AKBA0.20

EVMN0.62

52W Performance

AKBA-71.9%

EVMN-69.1%

YTD Performance

AKBA-48.3%

EVMN-63.9%

% from 52W High

AKBA-75.0%

EVMN-81.2%

% from 52W Low

AKBA0.0%

EVMN3.8%

Asset Turnover (TTM)

AKBA0.60x

EVMN0.00x

FCF Yield (TTM)

AKBA13.7%

EVMN-55.4%

Earnings Yield (TTM)

AKBA-13.8%

EVMN-67.0%

Dividend Yield (TTM)

AKBAN/A

EVMNN/A

Rule of 40

AKBA21.0

EVMN-779.8

EV/GP/RG

AKBAN/A

EVMNN/A

Ticker research

View AKBA research View EVMN research

Metric	AKBA Akebia Therapeutics Inc	EVMN Evommune Inc
Market & Valuation
Market Cap	$215M	$225M
Enterprise Value	$252M	$166M
Price	$0.80	$6.25
P/E Ratio	N/A	N/A
P/S Ratio	0.98x	14.07x
EV/Sales	1.15x	10.38x
EV/EBITDA	49.22x	0.00x
P/B Ratio	9.58x	0.90x
P/FCF Ratio	7.30x	N/A
EV/FCF	8.54x	-1.33x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.35x	N/A
Revenue & Growth
Revenue (TTM)	$219M	$16M
Revenue Growth (YoY)	7.5%	N/A
Forward Rev Growth	-33.0%	881.5%
Profitability
Gross Margin (TTM)	81.5%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1.9%	-1097.9%
Net Margin (TTM)	-13.5%	-943.2%
FCF Margin (TTM)	13.4%	-779.8%
Net Income (TTM)	$-30M	$-151M
FCF (TTM)	$29M	$-125M
EPS (TTM)	-$0.11	-$4.18
ROE (TTM)	-9374.0%	-4676.0%
ROA (TTM)	-817.0%	-4337.0%
ROIC (TTM)	-1321.0%	-4661.0%
Financial Health
Cash	$156M	$60M
Debt	$192M	$952K
Net Cash/Debt	$-37M	$59M
Current Ratio (TTM)	1.43x	11.68x
Quick Ratio (TTM)	1.31x	11.48x
Debt/Equity (TTM)	7.69x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.20	0.62
52W Performance	-71.9%	-69.1%
YTD Performance	-48.3%	-63.9%
% from 52W High	-75.0%	-81.2%
% from 52W Low	0.0%	3.8%
Efficiency & Yields
Asset Turnover (TTM)	0.60x	0.00x
FCF Yield (TTM)	13.7%	-55.4%
Earnings Yield (TTM)	-13.8%	-67.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	21.0	-779.8
EV/GP/RG	N/A	N/A
Ticker research	View AKBA research	View EVMN research